Olufunmilola Abraham

Real-world anti-amyloid therapy beyond traditional symptomatic populations: a longitudinal case series

Introduction Anti-amyloid monoclonal antibodies are approved as disease-modifying therapies for early Alzheimer’s disease (AD), but real-world evidence remains limited, particularly among individuals treated during preclinical or minimally symptomatic stages. This study characterized clinical and biomarker trajectories...